Skip to main content
Fig. 1 | BMC Rheumatology

Fig. 1

From: Nintedanib combined with immunosuppressive agents improves forced vital capacity in connective tissue disease-associated PF-ILD: a single-center study

Fig. 1

(A) Pulmonary function before and after NTB treatment. (B) Differences in pulmonary function changes between the NTB group and the NTB + IS group. FVC, forced vital capacity; DLCO, diffusing capacity for carbon monoxide; NTB, nintedanib; IS, immunosuppressive agents. For statistical analyses, *p < 0.05, **p < 0.01. P-value: Wilcoxon signed rank test, Wilcoxon rank sum test

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us